Published 10 hours ago • loading... • Updated 10 hours ago

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 ...

KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate

KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate

10 hours ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources1

Leaning Left1Leaning Right0Center0Last Updated10 hours agoBias Distribution

100% Left

100% Left

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Enid News & Eagle broke the news in 10 hours ago on Thursday, April 9, 2026.

Sources are mostly out of (0)